Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Mineralys Therapeutics, Inc. Common Stock (MLYS)

Pharmaceutical Preparations

https://mineralystx.com

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

150 N. RADNOR CHESTER ROAD, SUITE F200
RADNOR, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/10/2023

Market Cap

481,354,195

Shares Outstanding

41,110,000

Weighted SO

41,105,118

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

Beta

2.4569

Last Div

0.0000

Range

5.85-16.905

Chg

-0.0800

Avg Vol

227404

Mkt Cap

481354195

Exch

NASDAQ

Country

US

Phone

888-378-6240

DCF Diff

8.1576

DCF

1.3624

Div Yield

0.0000

P/S

0.0000

EV Multiple

-3.0742

P/FV

1.6469

Div Yield %

0.0000

P/E

-3.9924

PEG

0.0231

Payout

0.0000

Current Ratio

11.1984

Quick Ratio

11.1984

Cash Ratio

2.3895

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

77881.8750

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

0.0003

ROA

-0.3757

ROE

-0.4261

ROCE

-0.4637

NI/EBT

1.0000

EBT/EBIT

0.8897

EBIT/Rev

0.0000

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

0.0000

CF/Debt

0.0000

Equity Multi

1.0979

Rec Turnover

0.0000

Pay Turnover

0.0047

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-1.7736

FCF/Share

-1.7748

Cash/Share

1.3748

OCF/Sales

0.0000

FCF/OCF

1.0007

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

-1483.6780

Div&CapEx Cov

-1483.6780

P/BV

1.6469

P/B

1.6469

P/S

0.0000

P/E

-3.9924

P/FCF

-5.4952

P/OCF

-5.4579

P/CF

-5.4579

PEG

0.0231

P/S

0.0000

EV Multiple

-3.0742

P/FV

1.6469

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Mar 29, 18:30 Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 11, 11:30 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 GlobeNewswire Inc. Nov 02, 10:00 Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

Revenue Product Segmentation